Last reviewed · How we verify
NCT06633913
Concurrent TMS-fMRI
NA trial testing spTMS-TBS-spTMS in Healthy Control in 97 participants. Currently enrolling.
1 March 2028
Quick facts
| Lead sponsor | Jing Jiang |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 97 |
| Start date | 19 April 2024 |
| Primary completion | 1 March 2028 |
| Estimated completion | 31 January 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- spTMS-TBS-spTMS
Conditions studied
- Healthy Control — all drugs for Healthy Control →
- Depression — all drugs for Depression →
Sponsor
Jing Jiang
Who can join
Adults 18 to 65, any sex, with Healthy Control or Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to examine the neural mechanisms underlying transcranial magnetic stimulation (TMS) using concurrent functional magnetic resonance imaging (fMRI) in both healthy controls (HCs) and patients with high negative affect symptoms, such as depression. Approximately half male and half female participants aged 18-65 will be recruited. The main questions it aims to answer are: 1. Is the acute/transient effect induced by single-pulse TMS related to the long-term modulatory effect induced by repetitive TMS (rTMS)? 2. Do any of these effects predict negative affect symptoms, such as depression? Participants will: 1. Complete several tests to assess their cognitive abilities and emotional states 2. Undergo several brain scans, including resting-state fMRI, structural MRI, diffusion tensor imaging (DTI), and task fMRI 3. Have two different types of TMS sequences, single-pulse and repetitive pulses, administered to specific brain regions while undergoing fMRI
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06633913
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Control
Currently open trials in the same condition.
- NCT06727877 — Predictive Diagnosis of Ulcero-Necrotizing EnteroColitis in Premature Babies Using an Artificial Intelligence Approach B · NA · recruiting
- NCT07328178 — Analysis of the Role of IgE Proteoforms in Health and Disease · recruiting
- NCT06975202 — Test-retest Reliability and Agreement of Trunk Muscle Activation in Pain-free Persons · recruiting
- NCT07392411 — Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Bioma · recruiting
- NCT05683184 — OMAR Opioid Use Disorder · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06633913 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jing Jiang
- Last refreshed: 12 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06633913.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing